Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of

Amarin Announces New Clinical Data Showing Significant Reductions in
Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)

BEDMINSTER, N.J., and DUBLIN, Ireland, April 8, 2013 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today additional data from Amarin's
previously announced MARINE and ANCHOR Phase 3 clinical trial results of
Vascepa^® (icosapent ethyl) related to the effect of Vascepa on apolipoprotein
C-III (Apo C-III). The lipoprotein Apo C-III is thought to inhibit the
clearance of triglycerides from the blood. People who do not produce Apo C-III
have lower levels of triglycerides and lower instances of cardiovascular
disease.

In Amarin's MARINE and ANCHOR trials, the 4 gram dose of Vascepa achieved
reductions in Apo C-III levels of 25.1% (p<0.0001) and 19.2% (p<0.0001)
compared to placebo, respectively. Amarin previously announced the efficacy
and safety results of its MARINE and ANCHOR trials, including achievement of
the primary endpoints of these studies with respect to triglyceride reduction
as well as the positive effect of Vascepa with respect to levels of
apolipoprotein B (Apo B), non-high-density lipoprotein (non-HDL-C), total
cholesterol (TC), and very low density lipoprotein cholesterol (VLDL-C).The
data on Apo C-III were collected from post-hoc analyses of the MARINE and
ANCHOR trials.Amarin plans to present additional data related to Vascepa's
effect on Apo C-III at an upcoming scientific meeting.

"Amarin is proud of the robust performance of Vascepa in the MARINE and ANCHOR
studies," stated Steven B. Ketchum, Ph.D., President of Research and
Development of Amarin."The Apo C-III data announced today are another example
of these positive results." 

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

Forward-looking statements

This press release contains forward-looking statements, including statements
about the potential efficacy, safety and therapeutic benefits
ofAmarin'sproduct candidates,Amarin'sclinical trial results, and the
expected timing of future publication, including statements about the clinical
importance of certain biomarkers and the impact of Vascepa on such biomarkers.
These forward-looking statements are not promises or guarantees and involve
substantial risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected herein include
uncertainties associated generally with research and development, clinical
trials and related regulatory approvals, including the risk that historical
clinical trial results may not be predictive of future results in replicated
in larger patient populations. A further list and description of these risks,
uncertainties and other risks associated with an investment inAmarincan be
found inAmarin'sfilings with theU.S. Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K.Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof.Amarin undertakes no
obligation to update or revise the information contained in this press
release, whether as a result of new information, future events or
circumstances or otherwise.

Nothing in this press release should be construed as marketing the use of
Vascepa in any indication that has not been approved by theFDA.

CONTACT: Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo